Activity of a Novel 1,3-Beta-d-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata

Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata. The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill assays. The MIC range against wild-type strains was 1...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Ghannoum, M., Long, L., Isham, N., Hager, C., Wilson, R., Borroto-Esoda, K., Barat, S., Angulo, D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2019
Assuntos:
Susceptibility
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879250/
https://ncbi.nlm.nih.gov/pubmed/31570395
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01510-19
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares